X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (238) 238
anti-dyskinesia agents - therapeutic use (193) 193
anti-dyskinesia agents - pharmacology (152) 152
botulinum toxins - therapeutic use (133) 133
male (123) 123
animals (117) 117
clinical neurology (102) 102
neurosciences (102) 102
botulinum toxins - pharmacology (100) 100
female (91) 91
pharmacology & pharmacy (90) 90
index medicus (86) 86
botulinum toxin (80) 80
adult (59) 59
anti-dyskinesia agents - administration & dosage (59) 59
treatment outcome (58) 58
double-blind (51) 51
rats (48) 48
middle aged (47) 47
botulinum toxins - administration & dosage (44) 44
psychiatry (44) 44
anti-dyskinesia agents - adverse effects (42) 42
neurology (36) 36
dyskinesia, drug-induced - drug therapy (33) 33
aged (32) 32
cervical dystonia (29) 29
disease models, animal (28) 28
dose-response relationship, drug (28) 28
dystonia (26) 26
medicine & public health (26) 26
spasticity (26) 26
time factors (26) 26
efficacy (25) 25
haloperidol (25) 25
injections (24) 24
muscle spasticity - drug therapy (24) 24
botulinum toxins - adverse effects (23) 23
parkinsons-disease (23) 23
haloperidol - pharmacology (22) 22
mice (22) 22
parkinson's disease (22) 22
rats, sprague-dawley (22) 22
rats, wistar (22) 22
antipsychotic agents - adverse effects (21) 21
botulinum toxins, type a - therapeutic use (21) 21
pharmacology/toxicology (20) 20
placebo-controlled trial (20) 20
movement disorders (19) 19
care and treatment (18) 18
electromyography (18) 18
management (18) 18
a toxin (17) 17
dystonia - drug therapy (17) 17
injections, intramuscular (17) 17
safety (17) 17
gastroenterology & hepatology (16) 16
movement disorders - drug therapy (16) 16
severity of illness index (16) 16
tardive dyskinesia (16) 16
drug therapy (15) 15
dyskinesia (15) 15
injection (15) 15
research (15) 15
toxin type-a (15) 15
child (14) 14
dopamine (14) 14
therapy (14) 14
hemifacial spasm (13) 13
aged, 80 and over (12) 12
anti-dyskinesia agents (12) 12
anti-dyskinesia agents - chemistry (12) 12
article (12) 12
cerebral-palsy (12) 12
disease (12) 12
motor activity - drug effects (12) 12
muscle, skeletal - drug effects (12) 12
pain (12) 12
parkinson disease - drug therapy (12) 12
schizophrenia (12) 12
tardive-dyskinesia (12) 12
anti-dyskinesia agents - toxicity (11) 11
clinical trials as topic (11) 11
drugs (11) 11
muscle spasticity - etiology (11) 11
neurobiology (11) 11
quality of life (11) 11
quality-of-life (11) 11
schizophrenia - drug therapy (11) 11
torticollis - drug therapy (11) 11
anti-dyskinesia agents - pharmacokinetics (10) 10
antiparkinson agents - adverse effects (10) 10
antiparkinson agents - therapeutic use (10) 10
biomedicine (10) 10
blepharospasm (10) 10
blepharospasm - drug therapy (10) 10
botulinum toxins, type a (10) 10
dyskinesia, drug-induced - physiopathology (10) 10
haloperidol - therapeutic use (10) 10
health aspects (10) 10
levodopa - adverse effects (10) 10
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (283) 283
French (21) 21
Russian (4) 4
German (3) 3
Japanese (3) 3
Chinese (1) 1
Finnish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 01/2005, Volume 25, Issue 2, pp. 372 - 383
Journal Article
Journal Article
Neurobiology of Disease, ISSN 0969-9961, 2014, Volume 74, pp. 295 - 304
Journal Article
Neurobiology of Disease, ISSN 0969-9961, 2016, Volume 94, pp. 179 - 195
Abstract Pharmacological manipulation of the endocannabinoid system represents a promising therapy to alleviate L-3,4-dihydroxyphenylalanine (L-DOPA)-induced... 
Neurology | AIMs | NF-κB | CB1 | COX-2 | pAcH3 | LID | TRPV-1 | Neuroinflammation | ERK 1/2 | Cannabinoid | PPAR gamma | Anandamide | NITRIC-OXIDE SYNTHASE | PROLIFERATOR-ACTIVATED RECEPTORS | GAMMA PPAR-GAMMA | ABNORMAL INVOLUNTARY MOVEMENTS | NEUROSCIENCES | MESSENGER-RNA LEVELS | RAT MODEL | NF-kappa B | LEVODOPA-INDUCED DYSKINESIA | NF-KAPPA-B | CANNABINOID RECEPTOR AGONIST | PARKINSONS-DISEASE | Endocannabinoids - metabolism | Tyrosine 3-Monooxygenase - metabolism | Dyskinesia, Drug-Induced - physiopathology | Anti-Dyskinesia Agents - toxicity | Capsaicin - pharmacology | Male | NF-kappa B - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Oxidopamine | PPAR gamma - metabolism | TRPV Cation Channels - metabolism | Arachidonic Acids - metabolism | Dyskinesia, Drug-Induced - drug therapy | Parkinsonian Disorders - drug therapy | Parkinsonian Disorders - physiopathology | Mice, Inbred C57BL | Cannabidiol - pharmacology | Capsaicin - analogs & derivatives | Levodopa - toxicity | Dyskinesia, Drug-Induced - pathology | Polyunsaturated Alkamides - metabolism | Brain - drug effects | Receptor, Cannabinoid, CB1 - metabolism | Anti-Dyskinesia Agents - pharmacology | Animals | Parkinsonian Disorders - pathology | Cyclooxygenase 2 - metabolism | Brain - pathology | Histones - metabolism | Physiological aspects | Phenols | COX-2 inhibitors | Fatty acids | Movement disorders
Journal Article
Neurobiology of Disease, ISSN 0969-9961, 2014, Volume 74, pp. 66 - 75
Journal Article